TD Asset Management Inc Grows Stock Holdings in Corcept Therapeutics Incorporated $CORT

TD Asset Management Inc grew its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 16.6% during the third quarter, Holdings Channel.com reports. The fund owned 956,136 shares of the biotechnology company’s stock after purchasing an additional 136,254 shares during the quarter. TD Asset Management Inc’s holdings in Corcept Therapeutics were worth $79,464,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of CORT. Clearstead Advisors LLC boosted its holdings in shares of Corcept Therapeutics by 163.6% in the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 193 shares during the period. Golden State Wealth Management LLC bought a new stake in Corcept Therapeutics during the 2nd quarter valued at $28,000. Huntington National Bank lifted its holdings in shares of Corcept Therapeutics by 54.0% in the 2nd quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock worth $35,000 after buying an additional 168 shares during the period. Hantz Financial Services Inc. lifted its holdings in shares of Corcept Therapeutics by 598.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock worth $38,000 after buying an additional 395 shares during the period. Finally, Employees Retirement System of Texas bought a new position in shares of Corcept Therapeutics during the 2nd quarter worth $52,000. 93.61% of the stock is owned by hedge funds and other institutional investors.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Management reiterated a large 2026 revenue opportunity — $900M–$1B — as relacorilant’s oncology approval approaches, supporting upside if approval and commercial traction materialize. Article Title
• Neutral Sentiment: Analyst note: HC Wainwright trimmed a long‑term FY2030 EPS forecast (from $7.74 to $7.19) but maintained a Buy rating and $67 target, signaling continued analyst confidence in the longer‑term story despite near‑term misses.
• Negative Sentiment: Q4 results missed consensus — EPS and revenue came in below expectations (Q4 EPS ~$0.20; revenue ~$202M vs. higher estimates), prompting investor concern about growth momentum and guidance. Article Title
• Negative Sentiment: Multiple law firms have announced securities‑fraud class‑action filings and are soliciting lead‑plaintiff applicants (class period cited Oct 31, 2024–Dec 30, 2025); a wave of litigation notices increases legal and reputational risk and may pressure the stock. Representative alerts include Hagens Berman and Pomerantz. Article Title Article Title

Analysts Set New Price Targets

Several analysts recently weighed in on CORT shares. UBS Group assumed coverage on Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective for the company. Truist Financial set a $50.00 price target on shares of Corcept Therapeutics in a report on Wednesday, December 31st. HC Wainwright lowered their price target on shares of Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective on the stock. in a research note on Wednesday, December 31st. Finally, Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $77.17.

Insiders Place Their Bets

In other Corcept Therapeutics news, CEO Joseph K. Belanoff sold 40,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.77, for a total value of $3,190,800.00. Following the completion of the sale, the chief executive officer owned 2,701,370 shares of the company’s stock, valued at approximately $215,488,284.90. This trade represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph Douglas Lyon sold 5,000 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.53, for a total transaction of $397,650.00. Following the completion of the transaction, the insider directly owned 10,277 shares of the company’s stock, valued at $817,329.81. The trade was a 32.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 125,000 shares of company stock valued at $8,301,450 in the last 90 days. Corporate insiders own 20.80% of the company’s stock.

Corcept Therapeutics Stock Down 1.2%

NASDAQ:CORT opened at $35.78 on Friday. The company’s 50-day simple moving average is $45.37 and its 200-day simple moving average is $66.02. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 2.92. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $117.33. The stock has a market capitalization of $3.81 billion, a P/E ratio of 43.63 and a beta of 0.25.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. During the same period in the previous year, the company earned $0.26 EPS. The company’s revenue was up 11.1% on a year-over-year basis. On average, equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.